PriceTargets.com logo

Edgewise Therapeutics - EWTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.40
  • Forecasted Upside: 20.19%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$31.95 As of 11/20/2024 01:00 AM ET
▲ +0.44 (1.40%)

This chart shows the closing price for EWTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Edgewise Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EWTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EWTX

Analyst Price Target is $38.40
▲ +20.19% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Edgewise Therapeutics in the last 3 months. The average price target is $38.40, with a high forecast of $51.00 and a low forecast of $31.00. The average price target represents a 20.19% upside from the last price of $31.95.

This chart shows the closing price for EWTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Edgewise Therapeutics. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024WedbushBoost TargetOutperform ➝ Outperform$44.00 ➝ $45.00
10/11/2024Piper SandlerBoost TargetOverweight ➝ Overweight$48.00 ➝ $51.00
9/19/2024Truist FinancialBoost TargetBuy ➝ Buy$25.00 ➝ $33.00
9/17/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.00
8/16/2024WedbushReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
8/12/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$30.00 ➝ $31.00
7/25/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.00
7/10/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.00
7/9/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$27.00 ➝ $30.00
7/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$48.00 ➝ $48.00
6/26/2024WedbushReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
4/22/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$28.00 ➝ $32.00
4/17/2024Truist FinancialReiterated RatingBuy ➝ Buy$25.00
4/16/2024WedbushReiterated RatingOutperform ➝ Outperform$26.00
3/7/2024Piper SandlerInitiated CoverageOverweight$48.00
11/10/2023WedbushLower TargetOutperform ➝ Outperform$27.00 ➝ $23.00
8/11/2023WedbushReiterated RatingOutperform ➝ Outperform$27.00
6/30/2023JPMorgan Chase & Co.Boost TargetOverweight$24.00 ➝ $25.00
5/1/2023Truist FinancialInitiated CoverageBuy
11/4/2022Royal Bank of CanadaLower TargetOutperform$31.00 ➝ $29.00
8/24/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$5.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$8.00 ➝ $5.00
4/25/2022Leerink PartnersReiterated RatingOutperform
4/13/2022Royal Bank of CanadaInitiated CoverageOutperform$31.00
2/14/2022JPMorgan Chase & Co.Lower TargetOverweight$33.00 ➝ $32.00
1/28/2022The Goldman Sachs GroupInitiated CoverageNeutral
1/6/2022JPMorgan Chase & Co.Boost TargetOverweight$30.00 ➝ $33.00
4/20/2021WedbushInitiated CoverageOutperform$38.00
4/20/2021Leerink PartnersInitiated CoverageOutperform$34.00
4/20/2021JPMorgan Chase & Co.Initiated CoverageOverweight$34.00
4/19/2021The Goldman Sachs GroupInitiated CoverageNeutral$31.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 11 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 13 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Edgewise Therapeutics logo
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $31.95
Low: $31.06
High: $32.08

50 Day Range

MA: $30.37
Low: $16.86
High: $36.62

52 Week Range

Now: $31.95
Low: $5.93
High: $38.12

Volume

346,025 shs

Average Volume

722,790 shs

Market Capitalization

$3.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Edgewise Therapeutics?

The following sell-side analysts have issued research reports on Edgewise Therapeutics in the last year: JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, Truist Financial Co., and Wedbush.
View the latest analyst ratings for EWTX.

What is the current price target for Edgewise Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Edgewise Therapeutics in the last year. Their average twelve-month price target is $38.40, suggesting a possible upside of 20.2%. Piper Sandler has the highest price target set, predicting EWTX will reach $51.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $31.00 for Edgewise Therapeutics in the next year.
View the latest price targets for EWTX.

What is the current consensus analyst rating for Edgewise Therapeutics?

Edgewise Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EWTX will outperform the market and that investors should add to their positions of Edgewise Therapeutics.
View the latest ratings for EWTX.

What other companies compete with Edgewise Therapeutics?

Other companies that are similar to Edgewise Therapeutics include Zogenix, Kura Oncology, Intersect ENT, AnaptysBio and Arcturus Therapeutics. Learn More about companies similar to Edgewise Therapeutics.

How do I contact Edgewise Therapeutics' investor relations team?

Edgewise Therapeutics' physical mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The company's listed phone number is 720-262-7002 and its investor relations email address is [email protected]. The official website for Edgewise Therapeutics is www.edgewisetx.com. Learn More about contacing Edgewise Therapeutics investor relations.